Phase II study of weekly Vinorelbine and Topotecan administration treatment for refractory adult rhabdomyosarcoma previously treated by VAC regime
Phase 2
Recruiting
- Conditions
- Adult rhabdomyosarcoma with prior VAC therapy
- Registration Number
- JPRN-UMIN000008202
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
a) pregancy b) sereve infection c) interstitual pneumonia or lung fibrosis d) symptomatic CNS metastases e) HIV infection f) nuerotoxicity with >= grade 3
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression-free survival Overall survival Adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Vinorelbine and Topotecan's efficacy in refractory adult rhabdomyosarcoma post-VAC therapy?
How does the V-TOP trial regimen compare to standard-of-care treatments for VAC-refractory rhabdomyosarcoma in terms of clinical outcomes?
Are there specific biomarkers that could identify patients most likely to benefit from weekly Vinorelbine and Topotecan in the JPRN-UMIN000008202 trial?
What are the most common adverse events associated with weekly Vinorelbine and Topotecan combination therapy in adult rhabdomyosarcoma patients?
What other chemotherapeutic agents or combination strategies are being explored for refractory adult rhabdomyosarcoma alongside Vinorelbine and Topotecan?